secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scilex Holding Co (SCLX)
CIK:        0001820190
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-039211
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scilex licenses ZTlido and SP-103 to RoyaltyVest for ex-US markets; 50% net revenue share
--------------------------------------------------------------------------------

- Licensed ZTlido (lidocaine topical system 1.8%) and SP-103 for commercialization outside US; Licensor retains US and stated territories.
- RoyaltyVest pays Scilex Pharma 50% of net revenue from ex-US sales; annual $200K commitment until first regulatory approval.
- Licensee must use commercially reasonable efforts to obtain regulatory approval in at least one Major Market Country within 18 months.
- Scilex Pharma grants exclusive, non-transferable license; Scilex Holding Company provides parent guarantee for performance.
- Agreement effective February 22, 2025, replacing the October 2024 Rest of World License Term Sheet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1820190/000119312525039211/0001193125-25-039211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1820190/000119312525039211/d859484d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-039211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer